Clinical Trial Update: Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ribociclib in combination with PDR001 for metastatic hormone-receptor-positive (HR+) breast cancer, HER2-negative breast cancer, and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Epithelial Ovarian Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• PDR001
• Ribociclib (ribociclib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer, HER2-Negative Breast Cancer | Phase 1 | Status: TERMINATED